Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

NCT02027428 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

427

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Abraxane (Induction)
DRUG: Carboplatin (Induction)
DRUG: Abraxane (Maintenance)
OTHER: Best Supportive Care (Maintenance)
DRUG: Abraxane (Induction)
DRUG: Carboplatin (Induction)
OTHER: Best Supportive Care (Maintenance)

Sponsor

Celgene